论文部分内容阅读
目的评价雷公藤多苷联合贝那普利治疗免疫球蛋白A(Ig A)肾病的临床疗效及安全性。方法 96例Ig A肾病患者随机分为A组(n=31)、B组(n=33)和C组(n=32),分别口服贝那普利10 mg·d-1、雷公藤多苷60 mg·d-1及两药联合,疗程为3个月,分别于治疗前后测定患者24 h尿蛋白水平。结果 A、B和C组总有效率分别为35.5%,48.5%和75.0%,C组显著高于A、B组(P<0.05);C组患者治疗后24 h尿蛋白显著低于A和B组(P<0.05);3组患者药物相关不良反应差异无统计学意义(P>0.05)。结论雷公藤多苷联合贝那普利可显著提高Ig A肾病临床疗效,降低尿蛋白水平。
Objective To evaluate the clinical efficacy and safety of tripterygium glycosides combined with benazepril in treatment of immunoglobulin A (IgA) nephropathy. Methods Ninety-six patients with IgA nephropathy were randomly divided into group A (n = 31), group B (n = 33) and group C (n = 32) Glycosides 60 mg · d-1 and the two drugs, the course of treatment was 3 months, respectively, before and after treatment in patients with 24 h urinary protein levels. Results The total effective rates in groups A, B and C were 35.5%, 48.5% and 75.0%, respectively, while those in group C were significantly higher than those in groups A and B (P <0.05) Group B (P <0.05). There was no significant difference in drug-related adverse reactions between the three groups (P> 0.05). Conclusion Tripterygium glycosides combined with benazepril can significantly improve the clinical efficacy of IgA nephropathy, reduce urinary protein levels.